Dr. Srinivasan is a senior scientist working for a reputed biotechnology company known for its cutting-edge research in pharmaceuticals. Dr. Srinivasan is heading a research team working on a new drug aimed at treating a rapidly spreading variant of a new viral infectious disease. The disease has been rapidly spreading across the world and the cases reported in the country are increasing. There is huge pressure on Dr. Srinivasan’s team to expedite the trials for the drug as there is significant market for it, and the company wants to get the first-mover advantage in the market. During a team meeting, some senior team members suggest some shortcut for expediting the clinical trials for the drug and for getting the requisite approvals. These include manipulating data to exclude some negative outcomes and selectively reporting positive results, foregoing the process of informed consent and using compounds already patented by a rival company, rather than developing one’s own component. Dr. Srinivasan is not comfortable taking such shortcuts, at the same time he realises meeting the targets is impossible without using these means. (a) What would you do in such a situation? (b) Examine your options and consequences in the light of the ethical questions involved. (c) How can data ethics and drug ethics save humanity at large in such a scenario? (Answer in 250 words). (UPSC Mains 2024 GS4 Ethics Paper)

Ethical Dilemma of Dr. Srinivasan

Dr. Srinivasan faces a conflict between scientific integrity and commercial pressure to expedite a drug for a rapidly spreading viral disease.

Ethical issues involved:

• Scientific integrity: Data manipulation violates honesty, objectivity and the credibility of science.
• Patient safety: Shortcuts may compromise informed consent, clinical-trial standards and patient welfare.
• Intellectual property: Unauthorized use of patented compounds violates legal and ethical principles of fair competition.
• Social responsibility: Scientists have a duty to protect public health, particularly during a health emergency.

(a) My Approach

As Dr. Srinivasan, I would reject unethical shortcuts while pursuing legitimate ways to accelerate research.

1. Uphold integrity (Deontology): Refuse data falsification or manipulation, as truthfulness is a fundamental professional duty.
2. Protect patients: Ensure informed consent, safety monitoring and scientifically valid trials.
3. Transparent dialogue: Explain to management the long-term risks of misconduct, including patient harm, legal consequences and loss of public trust.
4. Responsible acceleration (Utilitarianism): Seek additional resources, collaboration and permissible expedited regulatory pathways to save lives without compromising safety.
5. Escalate if necessary: Consult institutional ethics committees or regulators if unethical practices are insisted upon.
6. Respect IP: Use licensing, collaboration or develop original compounds rather than infringing patents.

(b) Options

I would choose Option 3, Adhering to Ethical Standards, as the primary course of action, while adopting Option 4 wherever intellectual-property issues arise. This balances patient safety, scientific integrity, legal compliance and social responsibility, while pursuing legitimate ways to accelerate drug development.

(c) Data and Drug Ethics

Data ethics ensures accuracy, transparency and accountability. Drug ethics safeguards informed consent, patient welfare and rigorous testing.

R.K. Merton's scientific ethos—Communalism, Universalism, Disinterestedness and Organized Skepticism—reinforces that science must serve society, remain objective, minimize vested interests and remain open to scrutiny.

Thus, ethical science ensures that the pursuit of a cure does not itself become a source of harm.